Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

Blood (2018) 132 (Supplement 1): 4936.

https://doi.org/10.1182/blood-2018-99-111609

Published: 2018

Journal Articles

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Marlijn Hoeks, MD, Saskia Langemeijer, MD PhD, Louise De Swart, MD, Tim Bagguley, Corine van Marrewijk, PhD, David Bowen, MD PhD, Jaroslav Cermak, Eva Hellstrom-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, Marian G.J. Van Kraaij, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic J Culligan, Marta Krejci, MD PhD, Jackie Droste, PhD, Alexandra Smith, PhD, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2016) 128 (22): 4327.

https://doi.org/10.1182/blood.V128.22.4327.4327

Published: 2016

Journal Articles

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects a

Ulrich Moebius, PhD, Werner Feuerer, MD, Edgar Fenzl, MD, Rachel van Swelm, PhD, Dorine W. Swinkels, MD PhD, Andreas Hohlbaum, PhD

Blood (2015) 126 (23): 536.

https://doi.org/10.1182/blood.V126.23.536.536

Published: 2015

Journal Articles

The Donation Interval of 56 Days Requires Extension to 180 Days for Whole Blood Donors to Recover from Disturbances in Iron Homeostasis

Nienke N.Schotten, MSc, Pieternel C Pasker-de Jong, PhD, Diego Moretti, PhD, Michael Bruce Zimmermann, MD, Marian G Kraaij, MD PhD, Dorine W. Swinkels, MD PhD

Blood (2015) 126 (23): 774.

https://doi.org/10.1182/blood.V126.23.774.774

Published: 2015

Journal Articles

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Louise De Swart, MD, Chloé Reiniers, Tim Bagguley, David Bowen, MD PhD, Jaroslav Cermak, MD PhD, Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, MD PhD, Gerwin Huls, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic Culligan, Marta Krejci, Corine van Marrewijk, Jackie Droste, PhD, Alexandra Smith, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2015) 126 (23): 2865.

https://doi.org/10.1182/blood.V126.23.2865.2865

Published: 2015

Journal Articles

International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders

Louise De Swart, MD, Jan C.M. Hendriks, Lisa Van der Vorm, Ioav Z. Cabantchik, PhD, Patricia J. Evans, PhD, Eldad A. Hod, MD, Gary M. Brittenham, MD, Yael Furman, Mirian C.H. Janssen, MD, Bart J Biemond, MD, Marius A. MacKenzie, MD PhD, Vera E.J.M. Mattijssen, MD, Raffaella Origa, MD, Renzo Galanello, MD, Robert C. Hider, Dorine W. Swinkels, MD PhD

Blood (2014) 124 (21): 4033.

https://doi.org/10.1182/blood.V124.21.4033.4033

Published: 2014

Journal Articles

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

Kai Riecke, MD, Stefan Zöllner, PhD, Malcolm Boyce, MD, Stephanie Vauléon, PhD, Dorine W. Swinkels, MD, PhD, Thomas Dümmler, PhD, Luciana Summo, PharmD PhD, Coby Laarakkers, BSc, Frank Schwoebel, PhD, Frank Fliegert, MD

Blood (2012) 120 (21): 2342.

https://doi.org/10.1182/blood.V120.21.2342.2342

Published: 2012

Journal Articles

Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia

Lucas van Eijk, MD, Dorine W. Swinkels, MD, PhD, John Aaron, Frank Schwoebel, PhD, Frank Fliegert, MD, Luciana Summo, PharmD PhD, Vauleon Stéphanie, PhD, Coby Laarakkers, BSc, Kai Riecke, MD, Peter Pikkers, MD PhD

Blood (2012) 120 (21): 3452.

https://doi.org/10.1182/blood.V120.21.3452.3452

Published: 2012

Journal Articles

Anemia in Hodgkin Lymphoma: The Role of Interleukin-6 and Hepcidin.

Stefan Hohaus, Barbara Vannata, Manuela Giachelia, Maria Ilaria Roselli, Giuseppina Massini, Annarosa Cuccaro, Maria Chiara Tisi, Marianna Criscuolo, Francesco D'Alo, Harold Tjalsma, Dorine W. Swinkels, MD, PhD, Maria Teresa Voso, Giuseppe Leone

Blood (2009) 114 (22): 3656.

https://doi.org/10.1182/blood.V114.22.3656.3656

Published: 2009

Journal Articles

Serum Ferritin Levels Are Associated with Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease.

Luca Valenti, Dorine W. Swinkels, MD, PhD, Larry Burdick, Paola Dongiovanni, Harold Tjalsma, Silvia Fargion, Anna Ludovica Fracanzani

Blood (2009) 114 (22): 5098.

https://doi.org/10.1182/blood.V114.22.5098.5098

Published: 2009

Journal Articles

High Levels of Growth Differentiation Factor 15 in Patients with Congenital Dyserythtopoietic Anemia Type I

Hannah Tamary, MD, Hanna Shalev, MD, Galit Avraham, MD, Meira Zoldan, Itai Levi, MD, Dorine W. Swinkels, MD, PhD, Toshihiko Tanno, PhD, Jeffery L Miller, MD

Blood (2008) 112 (11): 3456.

https://doi.org/10.1182/blood.V112.11.3456.3456

Published: 2008

Journal Articles

Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome

Luca Malcovati, MD, Matteo G Della Porta, MD, Coby M Laarakkers, MD, Anna Gallì, BSc, Riccardo Albertini, MD, Margherita Maffioli, MD, Ilaria Ambaglio, MD, Erica Travaglino, Rosangela Invernizzi, MD, Remigio Moratti, MD, Dorine W. Swinkels, MD, PhD, Mario Cazzola, MD

Blood (2008) 112 (11): 2676.

https://doi.org/10.1182/blood.V112.11.2676.2676

Published: 2008

Journal Articles

Determinants for Iron Overload-Related Disease in Siblings of Probands with Clinically Detected HFE Hereditary Hemochromatosis: The Hemochromatosis Family Study.

Esther M.G. Jacobs, Jan C.M. Hendriks, Herman G. Kreeftenberg, Sr., Richard A. de Vries, Joannes J.M. Marx, Cees Th. B. M. van Deursen, Anton F.H. Stalenhoef, Andre L.M. Verbeek, Dorine W. Swinkels, MD, PhD

Blood (2008) 112 (11): 1857.

https://doi.org/10.1182/blood.V112.11.1857.1857

Published: 2008

Journal Articles

Results of the First International Round Robin for the Quantification of Urinary and Plasma Hepcidin: Need for Standardization

Joyce JC Kroot, Erwin HJM Kemna, Sukhvinder Bansal, Mark Busbridge, Natascia Campostrini, Domenico Girelli, Robert C Hider, Vasiliki Koliaraki, Avgi Mamalaki, Gordana Olbina, Naohisa Tomosugi, Chris Tselepis, Douglas G Ward, Tomas Ganz, MD, PhD, Jan CM Hendriks, Dorine W. Swinkels, MD, PhD

Blood (2008) 112 (11): 120.

https://doi.org/10.1182/blood.V112.11.120.120

Published: 2008

NARROW

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects a

The Donation Interval of 56 Days Requires Extension to 180 Days for Whole Blood Donors to Recover from Disturbances in Iron Homeostasis

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia

Anemia in Hodgkin Lymphoma: The Role of Interleukin-6 and Hepcidin.

Serum Ferritin Levels Are Associated with Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease.

High Levels of Growth Differentiation Factor 15 in Patients with Congenital Dyserythtopoietic Anemia Type I

Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome

Determinants for Iron Overload-Related Disease in Siblings of Probands with Clinically Detected HFE Hereditary Hemochromatosis: The Hemochromatosis Family Study.

Results of the First International Round Robin for the Quantification of Urinary and Plasma Hepcidin: Need for Standardization

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only